Physician profile
Debra A Glitz
NPI 1326086059
$1,377.37
in general payments reported to CMS, 2019-2025
15 companies · $17.35 in 2025
The $17.35 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $306 · 2021: $43.35 · 2023: $136 · 2025: $17.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $377.57 | 2019-2021 | |
| Allergan, INC. | $246.35 | 2019-2020 | |
| Axsome Therapeutics, INC. | $136.15 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $114.19 | 2019 | |
| Lundbeck LLC | $91.19 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.00 | 2019-2020 | |
| Bausch Health US, LLC | $74.33 | 2019-2025 | Aplenzin |
| Neurocrine Biosciences, INC. | $69.06 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $58.91 | 2019 | |
| Alkermes, INC. | $37.33 | 2020-2021 | |
| Shire North American Group INC | $24.62 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.85 | 2019 | |
| Neuronetics, INC. | $20.71 | 2019 | |
| Alfasigma USA, INC. | $16.99 | 2020 | |
| Vanda Pharmaceuticals INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Glitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.